Herbal treatment for Polycystic Ovarian Syndrome

Effect of a Unani formulation on menstrual cyclicity in women with Polycystic Ovarian Syndrome - A single arm open labelled observational study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/01/023012

Enrollment

Registered

2020-01-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases Health Condition 2: E889- Metabolic disorder, unspecified

Interventions

Intervention1: Pimpinella anisum Linn.,Trigonella foenum gracum Linn.,Ruta graveolance Linn.,Rubia cordifolia Linn.,Vigna unguiculata Linn. : Lobia surkh and Hulba -3.5g each Majeeth and Aneesun -17.5

Eligibility

Inclusion criteria

Inclusion criteria: Patient in age group of 20-38 years. Patient meeting Rotterdam criteria20 (2 out of 3 criteria) Oligovulation or anovulation(Oligo oramenorrhoea) and Clinical evidence of Hyperandrogenism (acne, hirsutism) or Ultrasound finding of polycystic ovaries

Exclusion criteria

Exclusion criteria: Patients with Thyroid dysfunction, hyperprolactinemia,Systemic illnesses, malignancy, morbid obesity, H/o using hormonal pills & insulin sensitizers within 3 months of study enrollment,Pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
Changes in menstrual cyclicityTimepoint: Menstrual cyclicity will be assessed in every cycle during the trial.	—

Secondary

Measure	Time frame
changes in ovarian volume, BMI, Waist circumference and serum insulinTimepoint: secondary outcome will be assessed after completion of trial.	—

Countries

India

Contacts

Public ContactRummana Kauser Shabbir Ahmed

National Institute of Unani Medicine, Bengaluru

dr.ismaths@gmail.com9538274583

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026